Literature DB >> 7710928

Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes.

D W Shen1, S Akiyama, P Schoenlein, I Pastan, M M Gottesman.   

Abstract

Human liver carcinoma cells (BEL-7404) and human KB adenocarcinoma cells were selected by stepwise increases in cisplatin. Drug sensitivity assays indicated that the IC50 value for 7404-CP7.5 cells was 49 micrograms ml-1 cisplatin, 111-fold higher than for the parental hepatoma cells. The IC50 value for KB-CP10 cells was 38 micrograms ml-1 cisplatin, which is 1152-fold higher than for the parental KB cells. The 7404-CP7.5 cells were cross-resistant to methotrexate (39 x), 5-fluorouracil (23 x) and 6-mercaptopurine (13 x), but were sensitive to drugs which are known substrates for the multidrug transporter (P-glycoprotein), including colchicine, vinblastine and actinomycin D. Similar cross-resistance patterns were observed for KB-CP10 cells. No evidence of DNA amplification or expression of the MDR1 gene was found. One-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis showed increases in 52 kDa protein(s) in both the soluble cytosolic and crude membrane fractions in 7404-CP(r) cells and in KB-CP(r) cells. The amount of 52 kDa protein was proportional to the degree of resistance of the 7404-CP(r) cells to cisplatin. Two-dimensional gel analysis demonstrated that two polypeptides of molecular mass 52 and 50 kDa were overexpressed in the membrane fractions in both 7404-CP20 and KB-CP20 cells. Using amino acid microsequencing and Western blotting, major 52 kDa protein was identified as the mitochondrial heat shock protein hsp60. Two-dimensional gels of [35S]methionine-labelled polypeptides showed many other changes, including reduction in soluble proteins of approximately 57 kDa molecular weight in KB-CP20 cells, and of 35 kDa in both 7404-CP20 and KB-CP20 cells. These results suggest that alterations of certain proteins occur commonly in cisplatin-resistant cells, particularly proteins of molecular weight 52 and 50 kDa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710928      PMCID: PMC2033730          DOI: 10.1038/bjc.1995.134

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation.

Authors:  K Ueda; D P Clark; C J Chen; I B Roninson; M M Gottesman; I Pastan
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

2.  Alkylating agent resistance: in vitro studies with human cell lines.

Authors:  E Frei; C A Cucchi; A Rosowsky; R Tantravahi; S Bernal; T J Ervin; R M Ruprecht; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

5.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.

Authors:  A P Jekunen; D K Hom; J E Alcaraz; A Eastman; S B Howell
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

7.  Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.

Authors:  B A Teicher; C A Cucchi; J B Lee; J L Flatow; A Rosowsky; E Frei
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

8.  Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II).

Authors:  A C Plooy; M van Dijk; F Berends; P H Lohman
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

9.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

Authors:  V M Richon; N Schulte; A Eastman
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

10.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.

Authors:  D W Shen; A Fojo; J E Chin; I B Roninson; N Richert; I Pastan; M M Gottesman
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

View more
  28 in total

1.  Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein.

Authors:  Zahida Parveen; Thomas Stockner; Caterina Bentele; Sandra Pferschy; Martin Kraupp; Michael Freissmuth; Gerhard F Ecker; Peter Chiba
Journal:  Mol Pharmacol       Date:  2010-12-21       Impact factor: 4.436

2.  Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer.

Authors:  Jun Okamura; Yiping Huang; David Moon; Mariana Brait; Xiaofei Chang; Myoung Sook Kim
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

3.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

4.  Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.

Authors:  Ding-Wu Shen; Xing-Jie Liang; Toshihiro Suzuki; Michael M Gottesman
Journal:  Mol Pharmacol       Date:  2006-01-04       Impact factor: 4.436

5.  Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells.

Authors:  Qing Li; Yan Shu
Journal:  Pharm Res       Date:  2013-07-25       Impact factor: 4.200

6.  Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.

Authors:  Andrew S Goldsborough; Misty D Handley; Andrés E Dulcey; Kristen M Pluchino; Pavitra Kannan; Kyle R Brimacombe; Matthew D Hall; Gary Griffiths; Michael M Gottesman
Journal:  J Med Chem       Date:  2011-06-24       Impact factor: 7.446

7.  Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity.

Authors:  Poulomi Sengupta; Sudipta Basu; Shivani Soni; Ambarish Pandey; Bhaskar Roy; Michael S Oh; Kenneth T Chin; Abhimanyu S Paraskar; Sasmit Sarangi; Yamicia Connor; Venkata S Sabbisetti; Jawahar Kopparam; Ashish Kulkarni; Katherine Muto; Chitra Amarasiriwardena; Innocent Jayawardene; Nicola Lupoli; Daniela M Dinulescu; Joseph V Bonventre; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

8.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.

Authors:  S S Chauhan; X J Liang; A W Su; A Pai-Panandiker; D W Shen; J A Hanover; M M Gottesman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 9.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

10.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.